Skip to main content

Table 1 Clinical characteristics of the asthma patients who had visited emergency clinic at least once during the follow-up compared to those who had not

From: Long-term smoking increases the need for acute care among asthma patients: a case control study

 

Emergency visit

Emergency visit

Clinical characteristics

Yes

No

p-value 1

N of patients

117

227

 

Proportion of women

65.8%

75.3%

0.06

Age at diagnosis (mean ± SD)

42.6 ± 16.2

43.7 ± 17.1

not significant

Age at recruitment (mean ± SD)

58.5 ± 11.8

54.7 ± 12.6

0.006

Duration of asthma, years (mean ± SD)

15.7 ± 14.3

11.1 ± 12.0

0.001

BMI (mean ± SD)

26.8 ± 5.5

26.5 ± 5.6

not significant

Smoking status (%)

   

never

47.3%

68.9%

0.001(trend)

ex smoker

38.2%

27.1%

 

current smoker

14.5%

4.0%

 

Pack years (mean ± SD)

13.2 ± 19.7

8.4 ± 17.4

0.02

COPD as second diagnosis (%)

23.1%

8.4%

<0.001

Baseline FEV1 percentage of expected (mean ± SD)

75.3 ± 21.1

86.6 ± 17.2

<0.001

Baseline FVC percentage of expected (mean ± SD)

82.9 ± 17.2

91.3 ± 14.6

<0.001

Baseline PEF percentage of expected (mean ± SD)

80.7 ± 20.3

94.0 ± 19.6

<0.001

Baseline FEV1/FVC ratio (mean ± SD)

73.4 ± 11.8

77.9 ± 10.5

0.001

HRQoL score (mean ± SD)

8.9 ± 4.7

6.3 ± 4.5

<0.001

Proportion (%)of patients with

   

no co-morbidities

59.8

71.8

0.06

1 co-morbidity

33.3

23.3

 

≥2 co-morbidities

6.8

4.8

 

Proportion (%) of patients with co-existing

   

Cardiovascular disease 2

16.2

9.3

0.06

Psychiatric disorder 3

21.4

16.3

not significant

Diabetes

3.4

5.7

not significant

Alcohol abuse

7.0

4.0

not significant

Chronic sinusitis

16.1

8.5

0.04

Allergic rhinitis

39.3

35.1

not significant

Allergic exzema

19.3

20.9

not significant

ASA intolerance

10.4

6.6

not significant

Nasal polyposis

10.3

8.0

not significant

  1. 1Continuous variables were compared using nonparametric Mann–Whitney U-test and categorical variables using the Chi-Square test.
  2. 2Included coronary disease, cerebrovascular disease, and peripheral arterial occlusive disease.
  3. 3Medication used.